6 results

  • actiq

    (Fentanyl Citrate)
    Cephalon, LLC
    ACTIQ is indicated for managing breakthrough pain in cancer patients aged 16 and older who are already tolerant to around-the-clock opioid therapy for persistent cancer pain. It is not for use in opioid non-tolerant patients or for acute or postoperative pain management.

  • granix

    (tbo-filgrastim)
    Cephalon, LLC
    GRANIX is indicated for reducing the duration of severe neutropenia in adults and pediatric patients (1 month and older) with non-myeloid malignancies undergoing myelosuppressive anticancer treatments that are likely to cause febrile neutropenia.

  • herzuma

    (TRASTUZUMAB)
    Cephalon, LLC
    HERZUMA is indicated for adults with HER2 overexpressing breast cancer in adjuvant settings and for metastatic breast cancer, either in combination with specific chemotherapy regimens or as a single agent. It is also indicated for HER2 overexpressing metastatic gastric cancer in combination with cisplatin and capecitabine or 5-fluorouracil.

  • provigil

    (Modafinil)
    Cephalon, LLC
    PROVIGIL is indicated for improving wakefulness in adults with excessive sleepiness due to narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). It is not a treatment for the underlying causes of OSA, and CPAP should be prioritized if appropriate.

  • synribo

    (Omacetaxine Mepesuccinate)
    Cephalon, LLC
    SYNRIBO is indicated for adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) who have resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).

  • trisenox

    (Arsenic Trioxide)
    Cephalon, LLC
    TRISENOX is indicated for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) in combination with tretinoin. It is also used for inducing remission and consolidation in patients with relapsed or refractory APL, characterized by the t(15;17) translocation or PML/RAR-alpha gene expression.